Creating Value Through Breakthrough Science

VUV Analytics, Inc. has introduced the VUV LUMA Multi-Channel Vacuum Ultraviolet Absorbance Detector, providing best-in-class detector sensitivity, universal detection, and selectivity that seamlessly integrates into existing laboratory workflows. “LUMA represents the next logical step in our long-term product strategy,” said Clark Jernigan, CEO of VUV Analytics. “Since the introduction of our

BrightVolt, Inc., a global leader in the design, development, and manufacturing of safe, high energy and low cost solid-state Lithium-Ion batteries has successfully closed the first tranche of a $16M Series B financing round with significant investments by New Science Ventures (NSV) and Caterpillar Venture Capital Inc. (Caterpillar). Fresh funds

Ventyx Biosciences, Inc. (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, has announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief

VORAGO Technologies (https://voragotech.com) has announced a product portfolio expansion to include a new radiation-tolerant Arm® Cortex-M0 MCU, VA10805, as a cost-competitive and high reliability solution for LEO, New Space, SmallSat and CubeSat markets. "As commercialization of space continues to grow, so does the need for reliable, affordable, and immediately available

Isorg, a pioneer in Organic Photodetectors (OPDs) and large-area image sensors, has announced a capital increase of €16M in series C financing. Two major industrial investors, Sumitomo Chemical Co. Ltd and Mitsubishi Corporation, participated in the round. Greece-based Integrated Systems Development SA and five new French investors represented by fund

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis”) and Oxyrane UK Ltd (“Oxyrane”) are pleased to announce the initiation of a research collaboration. Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV-132 to initiate a phase 2 clinical trial in patients with long covid. It is estimated that up to 30% of patients

Zeotap, the leading Customer Data Platform, has launched a new integration with Google Customer Match, enabling marketers to leverage their first-party data to engage audiences at scale across Google Search, Shopping, Gmail, YouTube and Display. In doing so, the new integration provides an important solution to addressability when third-party cookies

Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership

Phase Four, the creator of the radio-frequency thruster for satellite propulsion, announced today that it has closed a Series B investment round of $26 million. The round was led by New Science Ventures LLC ("NSV"), a leading venture capital firm focused on building companies that leverage breakthrough science to create

Zeotap the leading Customer Data Platform, has today announced the launch of Predictive Audiences as part of its award-winning Customer Intelligence Platform (CIP). Designed to help marketing users increase the impact of their campaigns, it enables the creation and application of machine-learned predictive segments in just a few clicks. Predictive

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal

Zeotap, the Customer Intelligence Platform (CIP), has reported 126% ARR growth in 2020 among its latest milestones in growth. Building momentum from its $60.5 million Series C fundraising round last year, the company is capitalizing on the marketing industry’s move to better engage first-party data in the face of the

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, today announced that it has begun shipping its 7nm Speedster®7t AC7t1500 FPGAs to customers ahead of schedule. The Speedster7t family is purpose-built for high bandwidth workloads in a broad range of applications including AI/ML, 5G infrastructure, networking,

ABL Space Systems has closed a Series B investment round of $170 million at a valuation of $1.3 billion. The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. Participation in the round included existing ABL investors and new investments by Fidelity Management & Research

Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of VTX-958, a novel and selective allosteric TYK2 inhibitor.  In non-clinical studies, VTX-958 has shown potential to treat autoimmune diseases by

New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline of immunology programs. Ventyx Biosciences combines assets from three formerly

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI® was presented at the European Congress of Radiology (ECR) 2021 Online meeting, taking place March 3-10, 2021. During the congress, the Company also showcased the full suite

Isorg, a pioneer in organic photodetectors (OPDs) and large-area image sensors, today announces its Fingerprint Acquisition Profile (FAP) 10 module has received FBI certification, the first in this category of organic photodiode (OPD) based optical sensors. The FAP 10 biometrics module is now approved for use in security applications, in

iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included